{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:02Z","timestamp":1792265042904,"version":"4.4.0"},"reference-count":252,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jceh.2022.11.014","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:18:18Z","timestamp":1670379498000},"page":"273-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-2664","authenticated-orcid":false,"given":"Ajay","family":"Duseja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-2674","authenticated-orcid":false,"given":"S.P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-1676","authenticated-orcid":false,"given":"Arka","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padaki Nagaraja","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourdas","family":"Choudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-7140","authenticated-orcid":false,"given":"Sanjiv","family":"Saigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil C.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashim","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-2839","authenticated-orcid":false,"given":"Chundamannil E.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnadas","family":"Devadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotacherry T.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-3686","authenticated-orcid":false,"given":"Manas","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Wadhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-0036","authenticated-orcid":false,"given":"Narendra S.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-6605","authenticated-orcid":false,"given":"Preetam","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Nijhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrat K.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-6204","authenticated-orcid":false,"given":"Vivek A.","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh K.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2022.11.014_bib1","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jceh.2022.11.014_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cld.1141","article-title":"Nonalcoholic fatty liver disease: Indian perspective","volume":"18","author":"De","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jceh.2022.11.014_bib9","first-page":"310","article-title":"A\u00a0community-based study to determine the prevalence of nonalcoholic fatty liver disease (NAFLD) and its metabolic risk factors in urban and rural communities of north India","volume":"34","author":"Mahajan","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027244","article-title":"Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort","volume":"9","author":"Chalmers","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jceh.2022.11.014_bib11","article-title":"Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis","author":"Shalimar","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib12","first-page":"448","article-title":"Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT)","volume":"61","author":"Kalra","year":"2013","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.jceh.2022.11.014_bib13","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.4103\/jfmpc.jfmpc_1108_19","article-title":"Prevalence of fatty liver in metabolic syndrome","volume":"9","author":"Goyal","year":"2020","journal-title":"J\u00a0Fam Med Prim Care"},{"key":"10.1016\/j.jceh.2022.11.014_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12664-014-0525-4","article-title":"A\u00a0study of gender-wise risk association between fatty liver and metabolic syndrome components (Asia-Pacific criteria) in a South Indian urban cohort","volume":"34","author":"Srinivas","year":"2015","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib15","first-page":"434","article-title":"Clusters and components of metabolic syndrome (MeS) as a predictor of fatty liver. A cross sectional study","volume":"12","author":"Bhargav","year":"2021","journal-title":"J\u00a0Diabetol"},{"key":"10.1016\/j.jceh.2022.11.014_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11901-017-0378-2","article-title":"Natural history of NAFLD\/NASH","volume":"16","author":"Ekstedt","year":"2017","journal-title":"Curr Hepat Rep"},{"key":"10.1016\/j.jceh.2022.11.014_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jceh.2019.09.005","article-title":"Natural history of simple steatosis or nonalcoholic fatty liver","volume":"10","author":"De","year":"2020","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.jceh.2022.11.014_bib18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jceh.2021.02.002","article-title":"Experience with changing etiology and non-transplant curative treatment modalities for hepatocellular carcinoma in a real-life setting \u2013a retrospective descriptive analysis","volume":"11","author":"Tohra","year":"2021","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/met.2021.0104","article-title":"Clinicopathological profile and outcome of a large cohort of patients with nonalcoholic fatty liver disease from South Asia: interim results of the Indian consortium on nonalcoholic fatty liver disease (ICON-D)","volume":"20","author":"Duseja","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jceh.2022.11.014_bib20","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.4103\/2468-8827.291731","article-title":"World NCD Federation guidelines for prevention, surveillance and management of noncommunicable diseases at primary and secondary health-care for low resource settings","volume":"5","author":"Thakur","year":"2020","journal-title":"Int J Non-Commun Dis"},{"key":"10.1016\/j.jceh.2022.11.014_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib22","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13856","article-title":"The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 2: management and special groups","volume":"33","author":"Chitturi","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jceh.2015.02.006","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian national association for the study of the liver, endocrine society of India, Indian College of cardiology and Indian society of gastroenterology","volume":"5","author":"Duseja","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jhep.2021.09.002","article-title":"NAFLD vs MAFLD - it is not the name but the disease that decides the outcome in fatty liver","volume":"76","author":"De","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib28","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2020.10.015","article-title":"Non-alcoholic fatty liver disease: not time for an obituary just yet","volume":"74","author":"Singh","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jceh.2020.08.002","article-title":"Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease - not only premature but also confusing","volume":"11","author":"Duseja","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib30","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jceh.2022.11.014_bib31","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgh.15156","article-title":"Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Lu","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib33","first-page":"51","article-title":"Study and comparison of metabolic profile of lean and obese subjects with non-alcoholic fatty liver disease","volume":"68","author":"Shah","year":"2020","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.jceh.2022.11.014_bib34","first-page":"201","article-title":"Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome","volume":"57","author":"Uchil","year":"2009","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.jceh.2022.11.014_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1665-2681(19)31922-2","article-title":"Prevalence of non-alcoholic fatty liver disease: population-based study","volume":"6","author":"Amarapurkar","year":"2007","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/2230-8210.113758","article-title":"Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease?","volume":"17","author":"Kumar","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jceh.2022.11.014_bib37","first-page":"351","article-title":"Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes","volume":"59","author":"Agarwal","year":"2011","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.jceh.2022.11.014_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049286","article-title":"Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India","volume":"8","author":"Nigam","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2022.11.014_bib39","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1007\/s10620-006-9136-y","article-title":"The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West","volume":"52","author":"Duseja","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2022.11.014_bib40","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.3748\/wjg.v12.i21.3400","article-title":"Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians","volume":"12","author":"Madan","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12664-020-01020-3","article-title":"Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity","volume":"39","author":"Sinha","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.7869\/tg.118","article-title":"Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India","volume":"34","author":"Singh","year":"2013","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib43","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.23567","article-title":"Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease","volume":"51","author":"Das","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jceh.2021.01.004","article-title":"Nonalcoholic fatty liver in lean individuals: clinicobiochemical correlates of histopathology in 157 liver biopsies from healthy liver donors","volume":"11","author":"Choudhary","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jgh3.12117","article-title":"High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India","volume":"3","author":"Duseja","year":"2019","journal-title":"JGH Open"},{"key":"10.1016\/j.jceh.2022.11.014_bib46","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clinre.2014.08.014","article-title":"Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: is it different?","volume":"39","author":"Singh","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib47","first-page":"285","article-title":"A\u00a0case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease","volume":"129","author":"Bajaj","year":"2009","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jceh.2022.11.014_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/dia.2013.0165","article-title":"Comparison of characteristics between nonobese and overweight\/obese subjects with nonalcoholic fatty liver disease in a South Indian population","volume":"16","author":"Vendhan","year":"2014","journal-title":"Diabetes TechnolTher"},{"key":"10.1016\/j.jceh.2022.11.014_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7869\/tg.2012.86","article-title":"Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease","volume":"34","author":"Bhat","year":"2013","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib50","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1665-2681(19)31461-9","article-title":"Correlation of adipose tissue with liver histology in Asian Indian patients with nonalcoholic fatty liver disease (NAFLD)","volume":"11","author":"Choudhary","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","article-title":"Non-alcoholic fatty liver disease in lean individuals","volume":"1","author":"Albhaisi","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2022.11.014_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12664-020-01024-z","article-title":"Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity","volume":"39","author":"Lazar","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jceh.2022.11.014_bib54","first-page":"399","article-title":"Normal-weight central obesity: unique hazard of the toxic waist","volume":"65","author":"Bosomworth","year":"2019","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.jceh.2022.11.014_bib55","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.4103\/2230-8210.104124","article-title":"Comparision between body mass index and abdominal obesity for the screening for diabetes in healthy individuals","volume":"16","author":"Gopinath","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jceh.2022.11.014_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.7337","article-title":"Association of normal-weight central obesity with all-cause and cause-specific mortality among postmenopausal women","volume":"2","author":"Sun","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jceh.2022.11.014_bib57","first-page":"345","article-title":"The metabolic syndrome in South Asians: continuing escalation & possible solutions","volume":"125","author":"Misra","year":"2007","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jceh.2022.11.014_bib58","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/hep.23838","article-title":"Nonalcoholic fatty liver in a developing country is responsible for significant liver disease","volume":"52","author":"Duseja","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib59","first-page":"15","article-title":"Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis","volume":"25","author":"Duseja","year":"2004","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib60","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12664-017-0785-x","article-title":"Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India","volume":"36","author":"David","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib61","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/MEG.0b013e32835643f1","article-title":"Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants","volume":"24","author":"Nayak","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jgh3.12200","article-title":"Explant liver evaluation decodes the mystery of cryptogenic cirrhosis","volume":"4","author":"Jain","year":"2019","journal-title":"JGH Open"},{"key":"10.1016\/j.jceh.2022.11.014_bib63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.humpath.2009.06.021","article-title":"End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program","volume":"41","author":"Nayak","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jceh.2022.11.014_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/ijmr.IJMR_1456_17","article-title":"Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern","volume":"149","author":"Dhamija","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jceh.2022.11.014_bib65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: real life differs from published guidelines","volume":"9","author":"Rinella","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib68","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.26072","article-title":"Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?","volume":"57","author":"van der Poorten","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jceh.2019.07.008","article-title":"Extra-hepatic manifestations of nonalcoholic fatty liver disease: a review","volume":"10","author":"Tariq","year":"2020","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib70","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A\u00a0systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jceh.2022.11.014_bib71","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib72","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2022.11.014_bib73","first-page":"479","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease","volume":"12","author":"Vanjiappan","year":"2018","journal-title":"Diabetes MetabSyndr"},{"key":"10.1016\/j.jceh.2022.11.014_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1825142","article-title":"Endothelial dysfunction, a marker of atherosclerosis, is independent of metabolic syndrome in NAFLD patients","volume":"2020","author":"Narayan","year":"2020","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib75","first-page":"20","article-title":"Association between non- alcoholic fatty liver disease and left ventricular diastolic dysfunction in patients of type 2 diabetes","volume":"67","author":"Saluja","year":"2019","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.jceh.2022.11.014_bib76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7869\/tg.2012.101","article-title":"Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease","volume":"34","author":"Guleria","year":"2013","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib77","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jceh.2017.12.005","article-title":"Renal dysfunction in patients WithNonalcoholic fatty liver disease is related to the presence of diabetes mellitus and severity of liver disease","volume":"9","author":"Nampoothiri","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib78","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jceh.2019.02.005","article-title":"Screening of cardiovascular disease in nonalcoholic fatty liver disease: whom and how?","volume":"9","author":"Choudhary","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib79","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4103\/ijmr.IJMR_610_18","article-title":"Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome","volume":"151","author":"Chakraborty","year":"2020","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jceh.2022.11.014_bib80","first-page":"1065","article-title":"Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome","volume":"13","author":"Harsha Varma","year":"2019","journal-title":"Diabetes MetabSyndr"},{"key":"10.1016\/j.jceh.2022.11.014_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12072-015-9615-3","article-title":"Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center","volume":"9","author":"Agrawal","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2022.11.014_bib82","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11325-018-1678-7","article-title":"Non-alcoholic fatty liver disease is an independent risk factor for inflammation in obstructive sleep apnea syndrome in obese Asian Indians","volume":"23","author":"Bhatt","year":"2019","journal-title":"Sleep Breath"},{"key":"10.1016\/j.jceh.2022.11.014_bib83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0049475520945058","article-title":"Non-alcoholic fatty liver disease in patients with hypothyroidism presenting at a rural tertiary care centre in north India","volume":"51","author":"Grewal","year":"2021","journal-title":"Trop Doct"},{"key":"10.1016\/j.jceh.2022.11.014_bib84","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jceh.2022.07.174","article-title":"Higher prevalence of metabolic bone disease (MBD) but similar fracture risk in non-alcoholic fatty liver disease (NAFLD) compared to chronic viral hepatitis","volume":"12","author":"De","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2022.11.014_bib86","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clinre.2015.12.011","article-title":"Chronic hepatitis B and fatty liver: issues in clinical management","volume":"40","author":"Kumar","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib87","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2036.2005.02596.x","article-title":"Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications","volume":"22","author":"Sanyal","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2022.11.014_bib88","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.3748\/wjg.v20.i23.7089","article-title":"Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen","volume":"20","author":"Lonardo","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib89","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jceh.2017.01.112","article-title":"Can alcoholic liver disease and nonalcoholic fatty liver disease Co-exist?","volume":"7","author":"Mehta","year":"2017","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib90","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/liv.14671","article-title":"Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failure","volume":"41","author":"Duseja","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2022.11.014_bib91","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib92","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cld.2017.08.006","article-title":"The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom","volume":"22","author":"Gunn","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2022.11.014_bib93","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"American association for the study of liver diseases. Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib95","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib96","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1478-3231.2012.02820.x","article-title":"Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography","volume":"32","author":"de L\u00e9dinghen","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2022.11.014_bib97","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jceh.2018.02.010","article-title":"Controlled attenuation parameter for assessment of hepatic steatosis in Indian patients","volume":"9","author":"Rout","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib98","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12664-019-00991-2","article-title":"Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease","volume":"39","author":"Shalimar","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1590\/s0004-2803.201800000-07","article-title":"Measurement of controlled attenuation parameter: a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification - a prospective follow-up study","volume":"55","author":"Paul","year":"2018","journal-title":"Arq Gastroenterol"},{"issue":"3","key":"10.1016\/j.jceh.2022.11.014_bib100","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jceh.2021.10.003","article-title":"Diagnostic accuracy and optimal cut-off of controlled attenuation parameter for the detection of hepatic steatosis in Indian population","volume":"12","author":"Kuchay","year":"2021","journal-title":"J Clin ExpHepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib101","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jceh.2022.11.014_bib102","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients WithNonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib103","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.soard.2017.09.005","article-title":"Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients","volume":"14","author":"Garg","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jceh.2022.11.014_bib105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jceh.2019.09.002","article-title":"Role of magnetic resonance imaging in the monitoring of patients with nonalcoholic fatty liver disease: comparison with ultrasonography, lipid profile, and body mass index","volume":"10","author":"Makhija","year":"2020","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib106","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1148\/radiol.2301021176","article-title":"Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings","volume":"230","author":"Limanond","year":"2004","journal-title":"Radiology"},{"key":"10.1016\/j.jceh.2022.11.014_bib107","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib108","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib109","article-title":"Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2022.11.014_bib110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib111","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/jgh.15358","article-title":"FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery","volume":"36","author":"Anand","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jceh.2022.11.014_bib112","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jceh.2021.06.008","article-title":"FibroScan-AST (FAST) score for nonalcoholic steatohepatitis \u2013 validation in an Indian cohort","volume":"12","author":"De","year":"2021","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib113","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.jceh.2022.11.014_bib114","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2017.02.003","article-title":"Non-invasive evaluation of portal hypertension using ultrasound elastography","volume":"67","author":"Berzigotti","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib115","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients WithNonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib116","doi-asserted-by":"crossref","first-page":"254","DOI":"10.14309\/ajg.0000000000001054","article-title":"Role of noninvasive tests in clinical gastroenterology practices to identify patients WithNonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations","volume":"116","author":"Younossi","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib117","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000288","article-title":"Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population","volume":"6","author":"Kolhe","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib119","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jhep.2019.12.025","article-title":"FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"73","author":"Shah","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrgastro.2016.86","article-title":"Critical comparison of elastography methods to assess chronic liver disease","volume":"13","author":"Friedrich-Rust","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib121","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/ajg.2012.331","article-title":"Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease","volume":"107","author":"Wong","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib122","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib123","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","article-title":"Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease","volume":"68","author":"Wong","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2022.11.014_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249493","article-title":"Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis","volume":"16","author":"Kuroda","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2022.11.014_bib125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jceh.2020.06.005","article-title":"Comparison of elastography point quantification with transient elastography in patients with chronic viral hepatitis and nonalcoholic fatty liver disease: a pilot study","volume":"11","author":"Kapur","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib126","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib127","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib128","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib129","unstructured":"Directorate General of Health Services, MOHFW, Government of India. Operational guidelines for integration of non-alcoholic fatty liver disease (NAFLD) with NPCDCS. Available at: https:\/\/main.mohfw.gov.in\/newshighli ghts-42. Published 2021."},{"key":"10.1016\/j.jceh.2022.11.014_bib130","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"S1","key":"10.1016\/j.jceh.2022.11.014_bib131","first-page":"1","article-title":"Non-invasive fibrosis scores - validation in Indian patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD)","volume":"16","author":"Singh","year":"2022","journal-title":"Hepatology International"},{"key":"10.1016\/j.jceh.2022.11.014_bib132","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10620-012-2306-1","article-title":"Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation","volume":"58","author":"Kumar","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.jceh.2022.11.014_bib133","first-page":"281","article-title":"Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India","volume":"28","author":"Pathik","year":"2015","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib134","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib136","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib137","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib138","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib139","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2036.2011.04695.x","article-title":"Validation of the non-alcoholic fatty liver disease activity score","volume":"34","author":"Hjelkrem","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2022.11.014_bib140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00365521.2016.1230779","article-title":"SAF score and mortality in NAFLD after up to 41 years of follow-up","volume":"52","author":"Hagstr\u00f6m","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib141","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib142","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2022.11.014_bib143","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cld.31","article-title":"Histological assessment of nonalcoholic fatty liver disease in adults and children","volume":"1","author":"Brunt","year":"2012","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.1016\/j.jceh.2022.11.014_bib144","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2010.06.028","article-title":"Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease","volume":"54","author":"Ruffillo","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib145","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jceh.2022.11.014_bib146","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2022.11.014_bib147","first-page":"477","article-title":"APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH","volume":"101","author":"Kruger","year":"2011","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.jceh.2022.11.014_bib148","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2022.11.014_bib149","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S2468-1253(20)30367-8","article-title":"CAP for the detection of hepatic steatosis in clinical practice","volume":"6","author":"Ferraioli","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib151","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib152","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jgh.13219","article-title":"Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease","volume":"31","author":"de L\u00e9dinghen","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib153","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.12557","article-title":"Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease","volume":"29","author":"Chan","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib154","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib155","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib156","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy","volume":"344","author":"Bravo","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2022.11.014_bib157","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib158","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates","volume":"17","author":"Ando","year":"2021","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.1016\/j.jceh.2022.11.014_bib160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib161","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib162","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib163","first-page":"1271","article-title":"Nutrition and physical activity in Asian Indians with non-alcoholic fatty liver: a case control study","volume":"13","author":"Bhatt","year":"2019","journal-title":"Diabetes MetabSyndr"},{"key":"10.1016\/j.jceh.2022.11.014_bib164","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4254\/wjh.v4.i7.209","article-title":"Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease","volume":"4","author":"Bhat","year":"2012","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1440-1746.2005.04233.x","article-title":"Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis","volume":"21","author":"Sreenivasa Baba","year":"2006","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib166","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of \u2265 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2022.11.014_bib167","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib168","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/dia.2013.0178","article-title":"Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids (olive and canola oils) compared with control oil in male Asian Indians with nonalcoholic fatty liver disease","volume":"16","author":"Nigam","year":"2014","journal-title":"Diabetes TechnolTher"},{"key":"10.1016\/j.jceh.2022.11.014_bib169","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cld.1172","article-title":"Intermittent fasting as a treatment for nonalcoholic fatty liver disease: what is the evidence?","volume":"19","author":"Memel","year":"2022","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.1016\/j.jceh.2022.11.014_bib170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.39558","article-title":"Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials","volume":"4","author":"Patikorn","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jceh.2022.11.014_bib171","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib172","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2016.05.026","article-title":"Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver","volume":"65","author":"Sung","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib173","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/hep.29356","article-title":"Exercise and NAFLD: is it worth the effort?","volume":"66","author":"Schweitzer","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib174","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib175","doi-asserted-by":"crossref","first-page":"120","DOI":"10.14218\/JCTH.2019.00012","article-title":"Effect of exercise on NAFLD and its risk factors: comparison of moderate versus low intensity exercise","volume":"8","author":"Nath","year":"2020","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib176","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1038\/nutd.2017.31","article-title":"Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history","volume":"7","author":"Clamp","year":"2017","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.jceh.2022.11.014_bib177","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/jgh.13166","article-title":"Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation","volume":"31","author":"Carias","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib178","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jceh.2020.09.003","article-title":"Nutrition in chronic liver disease: consensus statement of the Indian national association for study of the liver","volume":"11","author":"Puri","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib179","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib180","first-page":"27","article-title":"Nonalcoholic fatty liver disease and obesity","volume":"55","author":"De","year":"2021","journal-title":"J\u00a0Postgrad Med Educ Res"},{"key":"10.1016\/j.jceh.2022.11.014_bib181","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.soard.2019.10.025","volume":"16","author":"Mechanick","year":"2020","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jceh.2022.11.014_bib182","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s11695-020-04497-1","article-title":"OSSI (obesity and metabolic surgery society of India) guidelines for patient and procedure selection for bariatric and metabolic surgery","volume":"30","author":"Bhasker","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.jceh.2022.11.014_bib183","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.28958","article-title":"Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis","volume":"65","author":"Klebanoff","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib184","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib185","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/obr.12647","article-title":"Early major complications after bariatric surgery in the USA, 2003-2014: a systematic review and meta-analysis","volume":"19","author":"Chang","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.jceh.2022.11.014_bib186","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.gie.2012.05.023","article-title":"Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study","volume":"76","author":"Lee","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jceh.2022.11.014_bib187","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.gie.2009.06.036","article-title":"Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients","volume":"71","author":"Forlano","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jceh.2022.11.014_bib188","article-title":"Outcomes following Serial intragastric balloon therapy for obesity and nonalcoholic fatty liver disease in a single centre","volume":"2017","author":"Nguyen","year":"2017","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib189","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00592-013-0516-4","article-title":"Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding","volume":"51","author":"Folini","year":"2014","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jceh.2022.11.014_bib190","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients WithNonalcoholic steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib191","first-page":"116","article-title":"EndoBarrier gastrointestinal liner in type 2 diabetic patients improves liver fibrosis as assessed by liver elastography","volume":"125","author":"Gollisch","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.jceh.2022.11.014_bib192","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jhepr.2019.10.006","article-title":"Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results","volume":"1","author":"van Baar","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2022.11.014_bib193","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.gie.2020.08.023","article-title":"Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty","volume":"93","author":"Hajifathalian","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jceh.2022.11.014_bib194","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s11695-015-1727-2","article-title":"A\u00a0systematic review of bariatric surgery in patients with liver cirrhosis","volume":"25","author":"Jan","year":"2015","journal-title":"Obes Surg"},{"key":"10.1016\/j.jceh.2022.11.014_bib195","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","article-title":"Increased perioperative mortality following bariatric surgery among patients with cirrhosis","volume":"9","author":"Mosko","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib196","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cgh.2020.10.034","article-title":"AGA clinical practice update on bariatric surgery in cirrhosis: expert review","volume":"19","author":"Patton","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib197","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12664-016-0643-2","article-title":"Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation","volume":"35","author":"Choudhary","year":"2016","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib198","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib199","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/13543784.2021.1951701","article-title":"Anti-diabetic drugs and NASH: from current options to promising perspectives","volume":"30","author":"Smati","year":"2021","journal-title":"Expert OpinInvestig Drugs"},{"key":"10.1016\/j.jceh.2022.11.014_bib200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","article-title":"Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map","volume":"53","author":"Kumar","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2022.11.014_bib201","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Said","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.jceh.2022.11.014_bib203","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2022.11.014_bib204","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2022.11.014_bib205","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2022.11.014_bib206","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jceh.2022.11.014_bib207","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2022.11.014_bib208","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jceh.2022.11.014_bib209","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/00365521.2011.634024","article-title":"Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression","volume":"47","author":"Ekstedt","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib211","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib212","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib213","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib214","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib215","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2022.11.014_bib216","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib217","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib218","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jceh.2019.06.004","article-title":"Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease","volume":"9","author":"Choudhary","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib219","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib220","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2022.11.014_bib221","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820974917","article-title":"The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"13","author":"Abdel-Maboud","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jceh.2022.11.014_bib222","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jgh.15221","article-title":"Systematic review with meta-analysis: the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease","volume":"36","author":"Vadarlis","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib223","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/hep.24767","article-title":"The TONIC trial: a step forward in treating pediatricnonalcoholic fatty liver disease","volume":"55","author":"Alkhouri","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib224","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients WithNonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2022.11.014_bib225","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib226","first-page":"S326","article-title":"A\u00a0prospective, multi-center, double-blind, randomized trial of saroglitazar 4 mg versus placebo in patients with non-alcoholic steatohepatitis (EVIDENCES II)","volume":"14","author":"Sarin","year":"2020","journal-title":"Hepatology International"},{"key":"10.1016\/j.jceh.2022.11.014_bib227","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2022.11.014_bib228","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jceh.2022.11.014_bib229","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.14844","article-title":"New drugs for NASH","volume":"41","author":"Albhaisi","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2022.11.014_bib230","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2022.11.014_bib231","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2022.11.014_bib232","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients WithNonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib233","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.15331","article-title":"Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"50","author":"Vilar-Gomez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2022.11.014_bib234","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib235","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/s41598-021-83782-0","article-title":"A\u00a0prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2022.11.014_bib236","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5604\/01.3001.0011.7387","article-title":"An overview of liver transplant pathology: data from a tertiary referral centre in western India","volume":"17","author":"Fonseca","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib237","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib238","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cld.2016.12.001","article-title":"Liver transplantation and bariatric surgery: best approach","volume":"21","author":"Suraweera","year":"2017","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2022.11.014_bib239","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/lt.25303","article-title":"Liver transplantation and bariatric surgery: timing and outcomes","volume":"24","author":"Diwan","year":"2018","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2022.11.014_bib240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5500\/wjt.v4.i2.81","article-title":"Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease","volume":"4","author":"Khullar","year":"2014","journal-title":"World J Transplant"},{"key":"10.1016\/j.jceh.2022.11.014_bib241","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/lt.24738","article-title":"Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil","volume":"23","author":"D'Avola","year":"2017","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2022.11.014_bib242","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/lt.23936","article-title":"Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis","volume":"20","author":"Vallin","year":"2014","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2022.11.014_bib243","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/tgh.2019.10.12","article-title":"Nonalcoholic steatohepatitis recurrence after liver transplant","volume":"5","author":"Taneja","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.11.014_bib244","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/lt.25338","article-title":"Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis","volume":"25","author":"Galvin","year":"2019","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jceh.2022.11.014_bib245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/TP.0000000000002485","article-title":"Management of recurrent and de novo NAFLD\/NASH after liver transplantation","volume":"103","author":"Germani","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2022.11.014_bib246","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cld.1094","article-title":"Review of clinical guidelines in the diagnosis of pediatric nonalcoholic fatty liver disease","volume":"18","author":"Hunter","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jceh.2022.11.014_bib247","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MPG.0b013e318252a13f","article-title":"Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee","volume":"54","author":"Vajro","year":"2012","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2022.11.014_bib248","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"Vos","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2022.11.014_bib249","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MPG.0000000000000632","article-title":"Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee","volume":"60","author":"Dezs\u0151fi","year":"2015","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2022.11.014_bib250","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/hep.26230","article-title":"Hedgehog pathway and pediatricnonalcoholic fatty liver disease","volume":"57","author":"Swiderska-Syn","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.11.014_bib251","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2020.07.034","article-title":"Progression of fatty liver disease in children receiving standard of care lifestyle advice","volume":"159","author":"Xanthakos","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2022.11.014_bib252","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688322005254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688322005254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:08:42Z","timestamp":1760854122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688322005254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":252,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0973688322005254"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2022.11.014","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2022.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}